Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

HIV-1-infection Clinical Trial

Official title:

Single-Dose Fasting and Fed Pilot BE Study in Healthy Males and Females Not of Childbearing Potential

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05030025
• Other study ID #: ABDL-TBP-1001
• Status: Completed
• Phase: Early Phase 1
• Start date: August 1, 2021
• Est. completion date: August 29, 2021

Study information

• Verified date: March 2022
• Source: Viatris Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The rationale for this study is to evaluate and understand the variability of a generic alternative of abacavir, dolutegravir and lamivudine dispersible tablets for PEPFAR submission to aide in the development of pivotal studies.

Description:

This study is to investigate the bioequivalence of Mylan's abacavir, dolutegravir and lamivudine dispersible tablets, 60 mg/5 mg/30 mg to ViiV's Triumeq Dispersible Tablets (5 mg GSK1349572 [dolutegravir]/ 60 mg abacavir/ 30 mg lamivudine) following administration of a single, oral 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg) dose of Mylan's abacavir, dolutegravir and lamivudine dispersible tablets or ViiV's Triumeq Dispersible Tablets administered under fasting and fed conditions. Adverse events will be monitored to ensure the safety and well-being of the healthy volunteers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: August 29, 2021
• Est. primary completion date: August 29, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria - Subject candidates must fulfill all of the following inclusion

criteria to be eligible for participation in the study, unless otherwise specified:

• 18 to 55 years old.
• Males and/or females not of child-bearing potential.
• Each subject is required to weigh at least 50 kg (110 lbs) for men and 48 kg (106 lbs) for women and have a Body Mass Index (BMI) value less than or equal to 30.0 kg/m2 but greater than or equal to 19.0 kg/m2.
• Adequate venous access in both arms.
• Only non-tobacco/non-nicotine subjects.
• Able to understand and sign the written Informed Consent Form.
• Willing to follow the protocol requirements and comply with protocol restrictions.
• All subjects should be judged by the Principal Investigator or Medical Sub- Investigator as normal and healthy during a pre-study medical evaluation performed within 28 days of the initial dose of study medication. Exclusion Criteria - Subject candidates must not be enrolled in the study if subject meet

any of the following criteria:

• Institutionalized subjects.
• Social Habits, Medications and Diseases will be evaluated.
• Use of certain foods and processed candies, gums food/drinks that contain sugar alcohols.
• Liver function tests (ALT, AST and total bilirubin).
• Subjects who are positive for the HLA-B*5701 allele.
• Subjects having Modified Patient Health Questionnaire (PHQ)-12 questionnaire score > 4.
• Subject has a creatinine clearance < 90 mL/min, as determined by the Cockroft-Gault equation.
• Any reason which, in the opinion of the Principal Investigator or Medical Sub- Investigator, would prevent the subject from safely participating in the study.
• Intolerance to venipuncture.
• Donation or loss of blood or plasma.
• Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.
• Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Medical Sub-Investigator, could contraindicate the subject's participation in this study.
• Allergy or hypersensitivity to abacavir, dolutegravir, lamivudine, other related products, or any inactive ingredients.

Related Conditions & MeSH terms

• HIV-1-infection

Intervention

Combination Product:
• abacavir, dolutegravir and lamivudine dispersible tablets
Abacavir, Dolutegravir and Lamivudine Dispersible Tablets, 60 mg/5 mg/30 mg Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
• Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine
Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)

Locations

Country	Name	City	State
Canada	Altasciences	Montréal	Quebec

Sponsors (2)

Lead Sponsor	Collaborator
Mylan Inc.	ViiV Healthcare

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak Plasma Concentration (Cmax)	Evaluation of Peak Plasma Concentration (Cmax)	2 weeks
Primary	Area under the plasma concentration versus time curve (AUC) 0-t	Plasma concentration-time curve from zero to the time of the last measurable time point t	2 weeks
Primary	Area under the plasma concentration versus time curve (AUC)0-8	Area under the plasma concentration-time curve from zero to infinity	2 weeks